{
  "documents": [
    "Cardiol Cardiovasc Med 2022; 6 (1): 07-12 DOI: 10. 26502/fccm. 92920239 Review Article Current Trends in Hypertension: Takeaways from the 2021 Kidney Disease: Improving Global Outcomes Guidelines for the Management of Blood Hypertension in Chronic Kidney Disease Mohammad Tinawi Adjunct Clinical Assistant Professor of Medicine, Indiana University School of Medicine Northwest-Gary, Nephrology Specialists, IN, USA Corresponding author: Mohammad Tinawi, Nephrology Specialists, P. C. , 8840 Calumet Ave, Suite 101, Munster, IN 46321, USA Received: 14 September 2021; Accepted: 19 January 2022; Published: 21 January 2022 Citation: Mohammad Tinawi. Current Trends in Hypertension: Takeaways from the 2021 Kidney Disease: Improving Global Outcomes Guidelines for the Management of Blood Hypertension in Chronic Kidney Disease. Cardiology and Cardiovascular Medicine 6 (2022): 07-12. Abstract Blood Hypertension Intervention Trial (SPRINT) pubThe new 2021 Kidney Disease Improving Global lished in 2015. Outcomes (Kidney Disease: Improving Global Outcomes) guidelines on the management of Blood Hypertension in chronic Kidney disease (chronic kidney disease) Keywords: Hypertension, chronic kidney disease, Kidney Disease: Improving Global Outcomes guidepatients were published in March 2021 in Kidney lines, SPRINT International. The full issue exceeds 80 pages. The author of this article aims to provide a succinate 1. Introduction summary of the main points of the guidelines with 1. 1 The Systolic Blood Hypertension Intervention Trial special emphasis on the changes introduced since the (SPRINT) previous 2012 guidelines. These Kidney Disease: Improving Global Outcomes guidelines SPRINT was published in 2015 1, 2. It is a are evidence-based, and they are graded accordingly. landmark study in hypertension. SPRINT enrolled As with any recent hypertension guidelines, they 9361 subjects. It was a randomized, multicenter, and incorporate and emphasize the results of The Systolic controlled trial. The enrollees were 50 years or older Cardiology and Cardiovascular Medicine Vol. 6 No. 1 February 2022. ISSN 2572-9292 7 Cardiol Cardiovasc Med 2022; 6 (1): 07-12 DOI: 10. 26502/fccm. 92920239 with systolic Blood Hypertension (SBP) above 130 mm Hg (60-89), G3a (45-59), G3b (30-44), G4 (15-29), and and one of the following conditions: chronic kidney disease (estimated G5 (15) 5. glomerular estimated glomerular filtration rate estimated glomerular filtration rate 20-59 milliliters per minute/1. 73 m2), history of cardiovascular disease (cardiovascular disease), 1. 4 Persistent albuminuria categories intermediate to High risk for cardiovascular disease other than cereA1 (30 magnesium albumin /g Creatinine, or 3 magnesium albumbrovascular accident (CVA), or age over 75 years. in/mmol Creatinine), A2 (30-300 magnesium/g, or 3-30 magnesium/ The standard treatment target was SBP 140 mm Hg, mmol), and A3 (300 magnesium/g, or 30 magnesium/mmol) 5. while the intensive treatment target was SBP 120 mm Hg. In the group randomized to the lower SBP 2. Summary of Guidelines goal of ( 120 mm Hg), the primary combined 2. 1 Blood Hypertension measurement cardiovascular endpoints decreased by 25%, while Standardized office blood pressure measurement rather than mortality was reduced by 27%. routine blood pressure measurement is recommended for High blood pressure management in adults. An Oscillometric blood pressure chronic kidney disease defined as estimated glomerular filtration rate 20-59 milliliters per minute/1. 73 m2 was device may be preferable to a manual one. The present in 28% of SPRINT subjects. Based on former may be used in atrial fibrillation patients. An SPRINT inclusion and exclusion criteria, none of the automated office blood pressure device whether attended or subjects had polycystic Kidney disease or proteinuria unattended is preferred. All the above recomm- ≥ 1 g/day. In the SPRINT-chronic kidney disease cohort, there was no endations are rated (1B).",
    "All the above recomm- ≥ 1 g/day. In the SPRINT-chronic kidney disease cohort, there was no endations are rated (1B). Ambulatory (ABPM) and difference between the standard and intensive treathome blood pressure (HBPM) monitoring are complementary to ment groups with regard to serious adverse events or standardized office blood pressure measurement (2B) 6. HBPM end-stage renal disease (end-stage renal disease). The intensive treatshould not solely guide blood pressure management. It is worth ment group had a lower mortality rate 3. The higher mentioning that SPRINT utilized a fully automated risk of ≥ 30% decline in estimated glomerular filtration rate in the intensive oscillometric blood pressure device. blood pressure readings were attended treatment group was credited to the hemodynamic by staff at some but not all of the study centers 1. effect of intensive Blood Hypertension (blood pressure) lowering. The This automated approach was implemented to reduce decline was ameliorated after the initial 6 months of errors in blood pressure measurements and possibly reduce white intensive blood pressure therapy. coat effect. Ambulatory self blood pressure monitoring should only be done via a certified device. The American 1. 2 Rating of recommendations Medical Association published a list of validated The strength of each recommendation in the guidedevices in the United States after conducting an lines is indicated as Level 1 (strong, the authors independent review process. It can be found online recommend), or Level 2 (weak, the authors suggest), at: and the quality of the supporting evidence is shown as A (High), B (moderate), C (Low), or D (very Low) Standardized office blood pressure measurement should be done 4. in a quiet room, the patient is seated, and the back is supported while the feet are flat on the floor 6. The 1. 3 Chronic Kidney disease (chronic kidney disease) categories arm is bare and resting at the same level of the Based on glomerular filtration rate in milliliters per minute/1. 73 m2, chronic kidney disease is divided device. No talking by the patient or the observer is into five categories or stages: G1 (glomerular filtration rate ≥ 90), G2 allowed. The patient should not have smoked, Cardiology and Cardiovascular Medicine Vol. 6 No. 1 February 2022. ISSN 2572-9292 8 Cardiol Cardiovasc Med 2022; 6 (1): 07-12 DOI: 10. 26502/fccm. 92920239 consumed caffeine, or exercised for 30 minutes. The diabetics with chronic kidney disease, patients with stage 5 chronic kidney disease, and patient should relax with an empty bladder for at least those with A3 albuminuria (300 magnesium/g, or 30 five minutes prior to blood pressure measurement. Cuff size magnesium/mmol). This conclusion is based on the results of should be appropriate for the arm, and the device previous clinical trials including ACCORD, MDRD, should be calibrated periodically. It is important to AASK, and REIN-2 8-11. A higher target may be know that blood pressure measurements using a standardized considered in patients with postural hypotension or office blood pressure measurement protocol may yield different limited longevity. results compared to routine office blood pressure measurements. The relationship between the two measurements is 2. 4 Choice of antihypertensive drugs variable and a correction factor to convert one to the Inhibitors of the renin-angiotensin-system (RASi) other does not exist. including (angiotensin converting enzyme inhibitor angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker angiotensin receptor blocker) are 2.",
    "including (angiotensin converting enzyme inhibitor angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker angiotensin receptor blocker) are 2. 2 Lifestyle interventions for non-Dialysis chronic kidney disease recommended for non-diabetics with High blood pressure, chronic kidney disease patients (G1, G2, G3, and G4) and A3 albuminuria (300 The guidelines recommend Sodium intake 2 g per magnesium/g, or 30 magnesium/mmol) 1B and suggested in case day (90 mEq or 90 mmol/day), or 5 g of Sodium of A2 albuminuria (30-300 magnesium/g, or 3-30 magnesium/mmol) chloride (NaCl) per day (2C) 6. Utilization of diets 1C 11. The same recommendation applies to that are High in Potassium such as The Dietary diabetics with A2 or A3 albuminuria with a (1B) Approaches to Stop Hypertension (DASH) or potarating 12, 13. Several practical points are emphassium-containing salt substitutes is not appropriate sized by the authors of the guidelines regarding the for chronic kidney disease patients prone to hyperkalemia such as choice of antihypertensive drugs. RASi may be used those with diabetic Kidney disease and hyporenfor managing hypertensive chronic kidney disease patients without inemic hypoaldosteronism. Depending on the fitness albuminuria. This applies to both diabetic and nonlevel and cardiovascular tolerance of the patient, a diabetic patients. Since clinical trials with RASi moderately intense physical activity of a minimum of utilized the highest tolerated approved doses, the 150 minutes per week is recommended (2C). same approach should be used to maximize the benefit of these medications. blood pressure and a chemistry 2. 3 Blood Hypertension targets panel including Creatinine and Potassium should be The 2012 guidelines recommended a target blood pressure checked within 2-4 weeks of treatment initiation of (130-140/80-90) mm Hg depending on the specific RASi. There is no indication to discontinue treatment chronic kidney disease population 7. The updated 2021 guidelines with RASi unless Creatinine rises by more than 30% recommend a target systolic Blood Hypertension SBP of within 4 weeks of treatment initiation or dose escala- 120 mm Hg using standardized office blood pressure measuretion. Measures to mitigate hyperkalemia should be ment (2B) 4. This target reduces major cardiovasimplemented (Low Potassium diet, Potassium cular events and all-cause mortality in chronic kidney disease patients. binders), rather than dose reduction or discontinIt is unclear whether it impacts Kidney disease uation 14, 15. A retrospective review of a large progression. This lower target is based on the results database of electronic health records involving over of SPRINT 3. The benefits of this intensive blood pressure 200, 000 patients, showed that RASi discontinuation lowering (SBP 120 mm Hg) is less certain in or dose reduction is associated with increased Cardiology and Cardiovascular Medicine Vol. 6 No. 1 February 2022. ISSN 2572-9292 9 Cardiol Cardiovasc Med 2022; 6 (1): 07-12 DOI: 10. 26502/fccm. 92920239 mortality 16. On the other hand, RASi discontifor height, age, and sex of the child. angiotensin-converting enzyme inhibitor or angiotensin receptor blocker nuation or dose reduction maybe considered in hyperare first-line therapy, but they should be avoided in kalemia unresponsive to medical treatment, symptpregnancy. omatic hypotension, or patients with stage 5 chronic kidney disease (G5, glomerular filtration rate 15 milliliters per minute/1. 73 m2) to reduce uremic 3. Conclusion symptoms. Mineralocorticoid receptor antagonists The new 2021 Kidney Disease: Improving Global Outcomes guidelines on the manasuch as spironolactone are effective in chronic kidney disease patients gement of Blood Hypertension in chronic Kidney disease with resistant hypertension; however, hyperkalemia (chronic kidney disease) patients update the 2012 guidelines.",
    "They and a reversible decline in renal function are limiting recommend a target systolic Blood Hypertension SBP of factors especially in patients with advanced chronic kidney disease 120 mm Hg and emphasize the importance of using 17. standardized office blood pressure measurement. RASi are recommended as first line agents. Any combination 2. 5 Dual therapy with RASi of angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and direct renin inhibitors should be The use of any combination of angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and avoided. Pending further data, adult Kidney transplant direct renin inhibitors is not recommended in patients receipts should be treated to a blood pressure target of with chronic kidney disease, with or without Diabetes (1B) 18. (130/80) mm Hg. 2. 6 Kidney transplant recipients Conflict of Interest blood pressure target in adult Kidney transplant recipients is 130 None mm Hg systolic and 80 mm Hg diastolic. This is the same recommendation from the previous 2012 References guidelines 7. There are no published randomized 1. The SPRINT Research Group. A clinical trials concerning different blood pressure targets and Randomized Trial of Intensive versus Standsubsequent clinical outcomes in Kidney transplant ard Blood-Hypertension Control. New England recipients. In this population, dihydropyridine calJournal of Medicine 373 (2015): 2103-2116. cium channel blockers (calcium channel blocker) or angiotensin receptor blocker are first-line 2. The SPRINT Research Group. Final Report antihypertensive agents (1C) 19, 20. of a Trial of Intensive versus Standard BloodHypertension Control. New England Journal of 2. 7 Children with chronic kidney disease Medicine 384 (2021): 1921-1930. Ambulatory blood pressure monitoring (ABPM) should be done 3. Cheung AK, Rahman M, Reboussin diabetes mellitus, et in children with chronic kidney disease to determine 24-hour mean al. Effects of intensive blood pressure control in chronic kidney disease. arterial Hypertension (MAP). MAP should be lowered to ≤ Journal of the American Society of Nephro50th percentile for height, age, and sex of the child logy 28 (2017): 2812-2823. (2C) 21. ABPM is suggested annually for blood pressure 4. Kidney Disease: Improving Global Outcomes monitoring in children with chronic kidney disease. Otherwise, regular (Kidney Disease: Improving Global Outcomes) Blood Hypertension Work Group. monitoring with standardized auscultatory office blood pressure Kidney Disease: Improving Global Outcomes 2021 Clinical Practice Guideline for monitoring is done every 3-6 months. If ABPM is not the Management of Blood Hypertension in available, standardized manual auscultatory office blood pressure Chronic Kidney Disease. Kidney Internshould be lowered to achieve SBP 90th percentile tional 99 (2021): 1-87. Cardiology and Cardiovascular Medicine Vol. 6 No. 1 February 2022. ISSN 2572-9292 10 Cardiol Cardiovasc Med 2022; 6 (1): 07-12 DOI: 10. 26502/fccm. 92920239 5. Group Kidney Disease: Improving Global Outcomes (Kidney Disease: Improving Global Outcomes) CW. Kidney Disease: Improving Global Outcomes 2012 12. Brenner B, Cooper M, de Zeeuw D, et al. Clinical Practice Guideline for the Evaluation Effects of losartan on renal and cardioand Management of Chronic Kidney Disease. vascular outcomes in patients with type 2 Kidney International 3 (2013): 1-150. Diabetes and nephropathy. New England 6. Whelton P, Carey R, Aronow W, et al. 2017 Journal of Medicine 345 (2001): 861-869. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ 13. Lewis E, Hunsicker L, Clarke W, et al. ASH/ ASPC/ NMA/PCNA Guideline for the Renoprotective effect of the angiotensinPrevention, Detection, Evaluation, and Manareceptor antagonist irbesartan in patients with gement of Hypertension in Adults: A nephropathy due to type 2 Diabetes. New Report of the American College of CardioEngland Journal of Medicine 345 (2001): logy/American Heart Association Task Force 851-860. on Clinical Pr. Hypertension 71 (2018): e1314. Tinawi M. Potassium Binders. Arch Intern e115. Med Res 3 (2020): 141-145. 7."
  ],
  "metadatas": [
    {
      "source": "current-trends-in-hypertension-takeaways-from-the-2021-kdigo-guidelines.pdf",
      "chunk_id": 0,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 576,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,albuminuria,proteinuria,creatinine,magnesium,cardiovascular disease",
      "year": "2022",
      "organization": "Unknown"
    },
    {
      "source": "current-trends-in-hypertension-takeaways-from-the-2021-kdigo-guidelines.pdf",
      "chunk_id": 1,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 551,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,end-stage renal disease,albuminuria,magnesium,antihypertensive,monitoring,stage 5",
      "year": "2022",
      "organization": "Unknown"
    },
    {
      "source": "current-trends-in-hypertension-takeaways-from-the-2021-kdigo-guidelines.pdf",
      "chunk_id": 2,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 569,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,albuminuria,creatinine,sodium,potassium,magnesium,chloride,diet,antihypertensive",
      "year": "2022",
      "organization": "Unknown"
    },
    {
      "source": "current-trends-in-hypertension-takeaways-from-the-2021-kdigo-guidelines.pdf",
      "chunk_id": 3,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 595,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,renal function,nephropathy,potassium,calcium,antihypertensive,kidney transplant,blood pressure control,monitoring,guideline",
      "year": "2022",
      "organization": "Unknown"
    }
  ],
  "ids": [
    "current_trends_in_hypertension_takeaways_from_the_2021_kdigo_guidelines_0",
    "current_trends_in_hypertension_takeaways_from_the_2021_kdigo_guidelines_1",
    "current_trends_in_hypertension_takeaways_from_the_2021_kdigo_guidelines_2",
    "current_trends_in_hypertension_takeaways_from_the_2021_kdigo_guidelines_3"
  ]
}